Det overordnede målet med Innovasjonsrammen 2016 er å stimulere…
Vaccibody AS today announced that the cohort review committee as well as the independent data monitoring board have completed their review of the interim analysis of the results from the phase I dosing part of the multicentre trial VB C-01. The two committees recommended continuation of the trial into the expansion phase IIa.
PCI Biotech and Ultimovacs initiate research collaboration
Two of the biotech companies in the Oslo Cancer Cluster, PCI Biotech and Ultimovacs, initiate research collaboration on cancer vaccination.
Read more >